Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.

Statler A, Hobbs BP, Radivoyevitch T, Siebenaller C, Mukherjee S, Advani AS, Gerds AT, Nazha A, Patel BJ, Carraway HE, Sekeres MA.

Blood. 2019 Nov 13;134(Supplement_1):16. doi: 10.1182/blood-2019-130319.

PMID:
31724007
2.

The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.

Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U.

Ann Hematol. 2019 Oct 25. doi: 10.1007/s00277-019-03799-4. [Epub ahead of print] Review.

PMID:
31650290
3.

Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.

Patel SS, Rybicki L, Pohlman B, Bolwell B, Gerds AT, Hamilton BK, Hanna R, Kalaycio M, Majhail NS, Sobecks R.

Hematol Oncol Stem Cell Ther. 2019 Oct 11. pii: S1658-3876(19)30078-0. doi: 10.1016/j.hemonc.2019.09.002. [Epub ahead of print]

4.

Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.

Hill BT, Rybicki LA, Urban TA, Lucena M, Jagadeesh D, Gerds AT, Dean RM, Sobecks RM, Pohlman B, Bolwell B, Kalaycio ME, Hamilton BK, Copelan EA, Majhail NS.

Biol Blood Marrow Transplant. 2019 Oct 11. pii: S1083-8791(19)30652-4. doi: 10.1016/j.bbmt.2019.09.033. [Epub ahead of print]

PMID:
31610237
5.

Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Hamilton BK, Rybicki LA, Grove D, Ferraro C, Starn J, Hodgeman B, Elberson J, Winslow V, Corrigan D, Gerds AT, Hanna R, Kalaycio ME, Sobecks RM, Majhail NS, Dweik RA.

Blood Adv. 2019 Sep 24;3(18):2732-2737. doi: 10.1182/bloodadvances.2019000345.

6.

Genomics of therapy-related myeloid neoplasms.

Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, Przychodzen BP, Jha BK, Hiwase D, Singhal D, Advani AS, Nazha A, Gerds AT, Carraway HE, Sekeres MA, Mukherjee S, Maciejewski JP, Radivoyevitch T.

Haematologica. 2019 Aug 14. pii: haematol.2019.219352. doi: 10.3324/haematol.2019.219352. [Epub ahead of print]

7.

Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.

Grunwald MR, Burke JM, Kuter DJ, Gerds AT, Stein B, Walshauser MA, Parasuraman S, Colucci P, Paranagama D, Savona MR, Mesa R.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):579-584.e1. doi: 10.1016/j.clml.2019.06.001. Epub 2019 Jun 13.

8.

Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Jun;81:105. doi: 10.1016/j.leukres.2019.04.006. Epub 2019 Apr 24. No abstract available.

PMID:
31029462
9.

Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?

Madanat YF, Gerds AT.

Best Pract Res Clin Haematol. 2019 Mar;32(1):104-113. doi: 10.1016/j.beha.2019.02.011. Epub 2019 Feb 26. Review.

PMID:
30927969
10.

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Gerds AT, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M.

Leuk Res. 2019 Apr;79:38-44. doi: 10.1016/j.leukres.2019.02.012. Epub 2019 Feb 28. Erratum in: Leuk Res. 2019 Jun;81:105.

PMID:
30849661
11.

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.

Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, Hanna R, Kalaycio M, Sekeres MA, Sobecks R, de Lima M, Majhail NS, Maciejewski J.

Bone Marrow Transplant. 2019 Aug;54(8):1281-1286. doi: 10.1038/s41409-019-0444-1. Epub 2019 Jan 17.

PMID:
30655603
12.

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H.

J Natl Compr Canc Netw. 2018 Dec;16(12):1500-1537. doi: 10.6004/jnccn.2018.0088.

PMID:
30545997
13.

Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation.

Patel SS, Rybicki LA, Corrigan D, Dumont C, Bolwell B, Dean R, Figueroa P, Hanna R, Liu H, Gerds AT, Hill B, Jagadeesh D, Kalaycio M, Pohlman B, Ricci K, Sobecks R, Lu W, Hamilton BK, Majhail NS.

Bone Marrow Transplant. 2019 May;54(5):775-781. doi: 10.1038/s41409-018-0380-5. Epub 2018 Oct 30.

PMID:
30375493
14.

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.

Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, Verma A, Hamid O, Walgren R, Pitou C, Li PL, Gerds AT.

Leuk Res. 2018 Aug;71:82-88. doi: 10.1016/j.leukres.2018.06.014. Epub 2018 Jun 30.

PMID:
30025280
15.

Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al.

Molenaar RJ, Sidana S, Radivoyevitch T, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1889-1892. doi: 10.1200/JCO.2018.78.4074. Epub 2018 May 3. No abstract available.

PMID:
29723096
16.

Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study.

Mascarenhas J, Virtgaym E, Stal M, Blacklock H, Gerds AT, Mesa R, Ganly P, Snyder D, Tabbara I, Tremblay D, Moshier E.

Ann Hematol. 2018 Aug;97(8):1369-1374. doi: 10.1007/s00277-018-3309-6. Epub 2018 Apr 3.

17.

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S.

JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818.

18.

Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation.

Patel SS, Rybicki LA, Corrigan D, Bolwell B, Dean R, Liu H, Gerds AT, Hanna R, Hill B, Jagadeesh D, Kalaycio M, Pohlman B, Sobecks R, Majhail NS, Hamilton BK.

Biol Blood Marrow Transplant. 2018 May;24(5):1029-1034. doi: 10.1016/j.bbmt.2018.01.016. Epub 2018 Jan 31.

19.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.

Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS.

Blood Cancer J. 2018 Jan 10;8(1):4. doi: 10.1038/s41408-017-0040-9.

20.

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1831-1839. doi: 10.1200/JCO.2017.75.0232. Epub 2017 Dec 18.

PMID:
29252123
21.

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience.

Sawalha Y, Hill BT, Rybicki LA, Sun D, Dean RM, Jagadeesh D, Hamilton BK, Gerds AT, Sobecks RM, Andresen S, Liu HK, Majhail NS, Pohlman B, Kalaycio ME, Bolwell BJ, Smith MR.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e95-e102. doi: 10.1016/j.clml.2017.11.002. Epub 2017 Dec 6.

PMID:
29208403
22.

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP.

Am J Hematol. 2018 Feb;93(2):E49-E52. doi: 10.1002/ajh.24980. Epub 2017 Dec 4. No abstract available.

23.

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Angelini D, Maciejewski JP, Majhail N, Sekeres MA, Mukherjee S.

Leukemia. 2018 Apr;32(4):952-959. doi: 10.1038/leu.2017.323. Epub 2017 Nov 6.

PMID:
29104287
24.

Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?

Gerds AT, Chan T.

Curr Hematol Malig Rep. 2017 Dec;12(6):582-591. doi: 10.1007/s11899-017-0424-8. Review.

PMID:
29064027
25.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.

J Natl Compr Canc Netw. 2017 Oct;15(10):1193-1207. doi: 10.6004/jnccn.2017.0157.

PMID:
28982745
26.

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.

Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S.

Br J Haematol. 2017 Dec;179(5):781-789. doi: 10.1111/bjh.14954. Epub 2017 Oct 4.

PMID:
28980314
27.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

28.

Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection.

Mehdi A, Rybicki L, Mossad S, Yurch M, Sekeres M, Gerds AT, Jagadeesh D, Hamilton B, Liu H, Dean R, Pohlman B, Sobecks R, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS, Copelan E, Hill BT.

Bone Marrow Transplant. 2017 Dec;52(12):1665-1667. doi: 10.1038/bmt.2017.184. Epub 2017 Sep 4. No abstract available.

PMID:
28869614
29.

Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.

Winter A, Rybicki L, Shah SN, Jagadeesh D, Gerds AT, Hamilton BK, Liu H, Dean R, Sobecks R, Pohlman B, Smith M, Kalaycio M, Bolwell BJ, Majhail NS, Hill BT.

Leuk Lymphoma. 2018 May;59(5):1195-1201. doi: 10.1080/10428194.2017.1369065. Epub 2017 Aug 30.

PMID:
28853617
30.

Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times.

Patel SS, Gerds AT.

Curr Hematol Malig Rep. 2017 Oct;12(5):455-460. doi: 10.1007/s11899-017-0406-x. Review.

PMID:
28822056
31.

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.

Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA.

Leukemia. 2017 Dec;31(12):2848-2850. doi: 10.1038/leu.2017.266. Epub 2017 Aug 18. No abstract available.

PMID:
28819282
32.

Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.

Thota S, Gerds AT.

Leuk Lymphoma. 2018 Apr;59(4):803-812. doi: 10.1080/10428194.2017.1357179. Epub 2017 Aug 3. Review.

PMID:
28771058
33.

Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.

Saygin C, Papadantonakis N, Cassaday RD, Liedtke M, Fischer K, Dunn T, Patel BJ, Sobecks R, Kalaycio M, Sekeres MA, Mukherjee S, Gerds AT, Hamilton BK, Carraway HE, Advani AS.

Leuk Lymphoma. 2018 Feb;59(2):363-371. doi: 10.1080/10428194.2017.1344842. Epub 2017 Jul 11.

PMID:
28693363
34.

Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study.

Bates D, Bolwell B, Majhail NS, Rybicki L, Yurch M, Abounader D, Kohuth J, Jarancik S, Koniarczyk H, McLellan L, Dabney J, Lawrence C, Gallagher L, Kalaycio M, Sobecks R, Dean R, Hill B, Pohlman B, Hamilton BK, Gerds AT, Jagadeesh D, Liu HD.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1567-1572. doi: 10.1016/j.bbmt.2017.05.015. Epub 2017 May 19.

35.

The association of histologic grade with acute graft-versus-host disease response and outcomes.

Narkhede M, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Hanna R, Hill B, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS, Ky Hamilton B.

Am J Hematol. 2017 Jul;92(7):683-688. doi: 10.1002/ajh.24749. Epub 2017 May 26.

36.

A New Style of Transplantation May Gain Points When Treating Older Patients with Acute Myeloid Leukemia.

Gerds AT, Mukherjee S.

Biol Blood Marrow Transplant. 2017 May;23(5):715-716. doi: 10.1016/j.bbmt.2017.03.018. Epub 2017 Mar 14. No abstract available.

37.

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W.

Biol Blood Marrow Transplant. 2017 Jun;23(6):971-979. doi: 10.1016/j.bbmt.2017.03.014. Epub 2017 Mar 10.

38.

Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.

Mustafa Ali M, Abounader DM, Rybicki LA, Yurch MA, Starn J, Ferraro C, Winslow V, Hamilton BK, Gerds AT, Liu H, Dean R, Hill BT, Pohlman B, Andresen S, Hanna R, Kalaycio M, Bolwell BJ, Majhail NS, Sobecks RM.

Biol Blood Marrow Transplant. 2017 May;23(5):776-781. doi: 10.1016/j.bbmt.2017.01.077. Epub 2017 Jan 17.

39.

Polycythemia Vera Management and Challenges in the Community Health Setting.

Gerds AT, Dao KH.

Oncology. 2017;92(4):179-189. doi: 10.1159/000454953. Epub 2017 Jan 18. Review.

40.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.

J Natl Compr Canc Netw. 2016 Dec;14(12):1572-1611.

PMID:
27956542
41.

The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.

Statler A, Radivoyevitch T, Siebenaller C, Gerds AT, Kalaycio M, Kodish E, Mukherjee S, Cheng C, Sekeres MA.

Leukemia. 2017 Aug;31(8):1808-1815. doi: 10.1038/leu.2016.374. Epub 2016 Dec 7.

PMID:
27924815
42.

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, Mukherjee S, Kalaycio M, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA.

Leukemia. 2016 Nov;30(11):2214-2220. doi: 10.1038/leu.2016.138. Epub 2016 May 20.

PMID:
27311933
43.

GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.

Nazha A, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill BT, Kalaycio M, Liu H, Pohlman B, Sobecks R, Sekeres MA, Majhail NS.

Bone Marrow Transplant. 2016 Dec;51(12):1642-1643. doi: 10.1038/bmt.2016.254. Epub 2016 Oct 10. No abstract available.

PMID:
27721371
44.

Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome.

Yang Z, Keel SB, Shimamura A, Liu L, Gerds AT, Li HY, Wood BL, Scott BL, Abkowitz JL.

Sci Transl Med. 2016 May 11;8(338):338ra67. doi: 10.1126/scitranslmed.aaf3006.

45.

Long-term survival of patients with therapy-related myeloid neoplasms after allogeneic hematopoietic cell transplantation-more than just a myth.

Mukherjee S, Gerds AT.

Bone Marrow Transplant. 2016 Jun;51(6):763-4. doi: 10.1038/bmt.2016.121. Epub 2016 May 9. No abstract available.

PMID:
27159180
46.

Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.

Hong S, Rybicki L, Abounader DM, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS.

Bone Marrow Transplant. 2016 Sep;51(9):1191-6. doi: 10.1038/bmt.2016.107. Epub 2016 Apr 25.

PMID:
27111046
47.

Let's talk about sex[uality]-related symptom burden in myeloproliferative neoplasms.

Gerds AT.

Cancer. 2016 Jun 15;122(12):1804-6. doi: 10.1002/cncr.30017. Epub 2016 Apr 12. No abstract available.

48.

Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

Hong S, Rybicki L, Abounader D, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1141-1144. doi: 10.1016/j.bbmt.2016.03.011. Epub 2016 Mar 16.

49.

Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Nazha A, Gerds AT.

Oncologist. 2016 Apr;21(4):475-80. doi: 10.1634/theoncologist.2015-0380. Epub 2016 Mar 14. Review.

50.

Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.

Hong S, Valent J, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill B, Kalaycio ME, Pohlman B, Reu F, Samaras C, Sobecks R, Majhail NS, Liu HD.

Bone Marrow Transplant. 2016 May;51(5):732-4. doi: 10.1038/bmt.2015.326. Epub 2016 Jan 4. No abstract available.

PMID:
26726941

Supplemental Content

Loading ...
Support Center